Clinical Trials Directory

Trials / Completed

CompletedNCT00003115

Epidural Hydromorphone Compared With Hydromorphone Infusion in Treating Patients With Prostate Cancer Undergoing Radical Prostatectomy

Spinal Effects of Epidural Hydromorphone

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
40 (estimated)
Sponsor
Roswell Park Cancer Institute · Academic / Other
Sex
Male
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

RATIONALE: Giving hydromorphone in different ways may relieve the pain associated with cancer surgery. PURPOSE: Randomized double-blinded phase III trial to compare the effectiveness of epidural hydromorphone with hydromorphone infusion in patients with prostate cancer undergoing radical prostatectomy.

Detailed description

OBJECTIVES: I. Define the duration of action of hydromorphone (spinal vs supraspinal) in patients who have undergone radical prostatectomy. II. Demonstrate that the duration of the analgesic effects of equal blood concentrations of hydromorphone is dependent on the method used to attain this concentration by comparing continuous epidural infusion with that of a continuous intravenous infusion. OUTLINE: This is a double blinded, randomized study. After all patients have undergone radical prostatectomy, hydromorphone is administered in two different ways. Patients receive either a hydromorphone bolus injection through an epidural catheter using a patient controlled analgesia pump or a hydromorphone bolus injection through an intravenous catheter using a patient controlled analgesia pump. Infusion for both groups is stopped at 24 hours. Patients are followed every 30 minutes for 6 hours. PROJECTED ACCRUAL: A total of 40 patients will be accrued into this study over a 3 year period.

Conditions

Interventions

TypeNameDescription
DRUGhydromorphone hydrochloride

Timeline

Start date
1996-06-01
Primary completion
2003-01-01
Completion
2004-02-01
First posted
2004-08-12
Last updated
2011-02-23

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00003115. Inclusion in this directory is not an endorsement.